macrocyclic lactams

Summary

Summary: LACTAMS forming compounds with a ring size of approximately 1-3 dozen atoms.

Top Publications

  1. ncbi Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer
    Gautam Maulik
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 8:620-7. 2002
  2. ncbi RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha
    Ye V Liu
    Vascular Biology Program, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Mol Cell 25:207-17. 2007
  3. ncbi Binding of p23 and hsp90 during assembly with the progesterone receptor
    J L Johnson
    Department of Biochemistry and Molecular Biology, Mayo Graduate School, Rochester, Minnesota 55905, USA
    Mol Endocrinol 9:670-8. 1995
  4. ncbi Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells
    Nicola J Mabjeesh
    Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 62:2478-82. 2002
  5. ncbi Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network
    Byoung Heon Kang
    Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Cell 131:257-70. 2007
  6. ncbi Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
    Paul Workman
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
    Cancer Lett 206:149-57. 2004
  7. ncbi A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
    Adeela Kamal
    Conforma Therapeutics Corporation, 9393 Towne Centre Drive, Suite 240, San Diego, California 92121, USA
    Nature 425:407-10. 2003
  8. ncbi Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells
    L Whitesell
    Department of Pediatrics, University of Arizona Health Sciences Center, Tucson 85724, USA
    Mol Endocrinol 10:705-12. 1996
  9. ncbi Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy
    Martin Herbst
    Neuroproteomics Group, Max Delbrueck Center for Molecular Medicine, Berlin, Germany
    Neurodegener Dis 4:254-60. 2007
  10. ncbi Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor
    P N Munster
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 7:2228-36. 2001

Research Grants

Detail Information

Publications182 found, 100 shown here

  1. ncbi Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer
    Gautam Maulik
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 8:620-7. 2002
    ..These results demonstrate that c-Met/HGF pathway is functional in SCLC, and it would be useful to target this pathway toward novel therapy...
  2. ncbi RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha
    Ye V Liu
    Vascular Biology Program, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Mol Cell 25:207-17. 2007
    ..Thus, RACK1 is an essential component of an O(2)/PHD/VHL-independent mechanism for regulating HIF-1alpha stability through competition with HSP90 and recruitment of the Elongin-C/B ubiquitin ligase complex...
  3. ncbi Binding of p23 and hsp90 during assembly with the progesterone receptor
    J L Johnson
    Department of Biochemistry and Molecular Biology, Mayo Graduate School, Rochester, Minnesota 55905, USA
    Mol Endocrinol 9:670-8. 1995
    ..A model is presented to relate these findings to previous models and another complex between hsp90, hsp70, and p60 that appears to be an intermediate in PR assembly...
  4. ncbi Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells
    Nicola J Mabjeesh
    Winship Cancer Institute, Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Res 62:2478-82. 2002
    ..Thus, benzoquinone ansamycin drugs and their derivatives, such as 17-allyl-aminogeldanamycin, are excellent candidates as small molecule drug inhibitors of HIF-1 overexpression in cancer cells...
  5. ncbi Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network
    Byoung Heon Kang
    Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Cell 131:257-70. 2007
    ..Therefore, Hsp90-directed chaperones are regulators of mitochondrial integrity, and their organelle-specific antagonists may provide a previously undescribed class of potent anticancer agents...
  6. ncbi Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
    Paul Workman
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
    Cancer Lett 206:149-57. 2004
    ..This article reviews the current status and future prospects for the exploitation of Hsp90 as a new molecular target for cancer treatment...
  7. ncbi A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
    Adeela Kamal
    Conforma Therapeutics Corporation, 9393 Towne Centre Drive, Suite 240, San Diego, California 92121, USA
    Nature 425:407-10. 2003
    ..These results suggest that tumour cells contain Hsp90 complexes in an activated, high-affinity conformation that facilitates malignant progression, and that may represent a unique target for cancer therapeutics...
  8. ncbi Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells
    L Whitesell
    Department of Pediatrics, University of Arizona Health Sciences Center, Tucson 85724, USA
    Mol Endocrinol 10:705-12. 1996
    ....
  9. ncbi Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy
    Martin Herbst
    Neuroproteomics Group, Max Delbrueck Center for Molecular Medicine, Berlin, Germany
    Neurodegener Dis 4:254-60. 2007
    ..We suggest that geldanamycin derivatives such as 17-DMAG should be considered for the development of a drug treatment for polyQ disorders and other neurodegenerative diseases involving protein aggregation...
  10. ncbi Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor
    P N Munster
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 7:2228-36. 2001
    ..These findings suggest that inhibition of Hsp90 function by 17-AAG enhances the apoptotic effects of cytotoxic agents. The sequence of drug administration and the RB status significantly influence efficacy...
  11. ncbi COMMD1 Promotes pVHL and O2-Independent Proteolysis of HIF-1alpha via HSP90/70
    Bart van De Sluis
    Complex Genetics Section, DBG Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 4:e7332. 2009
    ..Although HIF activity is mainly controlled by ubiquitination and protein degradation by the von Hippel Lindau (pVHL) tumor suppressor gene other mechanisms have recently been identified that regulate HIF signaling independently of pVHL...
  12. ncbi Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
    Ayana Sawai
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 68:589-96. 2008
    ....
  13. ncbi Genetic and biochemical analysis of p23 and ansamycin antibiotics in the function of Hsp90-dependent signaling proteins
    S P Bohen
    Laboratory of Biochemistry, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4255, USA
    Mol Cell Biol 18:3330-9. 1998
    ..Furthermore, while the presence of p23 decreases the sensitivity of Hsp90-dependent processes to ansamycin treatment, ansamycin antibiotics disrupt signaling through some mechanism other than altering the Hsp90-p23 interaction...
  14. ncbi Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent
    C E Stebbins
    Department of Biochemistry and Structural Biology, Cornell University Graduate School of Medical Sciences, New York, New York 10021, USA
    Cell 89:239-50. 1997
    ..This, and the pocket's similarity to substrate-binding sites, suggest that the pocket binds a portion of the polypeptide substrate and participates in the conformational maturation/refolding reaction...
  15. ncbi Hsp90 is essential in the filarial nematode Brugia pahangi
    Eileen Devaney
    Parasitology Group, Division of Infection and Immunity, Institute of Comparative Medicine, University of Glasgow, UK
    Int J Parasitol 35:627-36. 2005
    ..Thus, Hsp90 or some of its client proteins may provide novel targets for the chemotherapy of filarial infection...
  16. ncbi Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor-1alpha stabilization
    Dorthe M Katschinski
    Cell Physiology Group, Medical Faculty, Martin Luther University Halle, Germany
    Cell Physiol Biochem 14:351-60. 2004
    ....
  17. ncbi Hsp90 & Co. - a holding for folding
    J Buchner
    Institut fur Organische Chemie and Biochemie, Technische Universitat Munchen, Lichtenbergstr 4, 85747 München, Germany
    Trends Biochem Sci 24:136-41. 1999
    ....
  18. ncbi Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition
    Wenchang Guo
    Department of Pharmaceutical Sciences, School of Pharmacy and Cancer Center, University of Colorado Health Sciences Center, Denver, Colorado
    Cancer Res 65:10006-15. 2005
    ..In conclusion, these studies have shown that reduction of 17-AAG by NQO1 generates 17-AAGH2, a relatively stable hydroquinone that exhibits superior Hsp90 inhibition...
  19. ncbi CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation
    Leonard Petrucelli
    Mayo Clinic, Jacksonville, FL 32224, USA
    Hum Mol Genet 13:703-14. 2004
    ..Hsp70/CHIP may therefore play an important role in the pathogenesis of tauopathies and also represents a potential therapeutic target...
  20. ncbi Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice
    Hai-ying Shen
    Molecular Neuropharmacology Laboratory, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Biol Chem 280:39962-9. 2005
    ....
  21. ncbi The Hsp90 chaperone complex as a novel target for cancer therapy
    M P Goetz
    Division Medical Oncology, Department of Biochemistry, Mayo Graduate School, Rochester, MN 55905, USA
    Ann Oncol 14:1169-76. 2003
    ..Early results from phase I studies indicate that 17-AAG administration results in an acceptable toxicity profile while achieving in vivo disruption of client proteins...
  22. ncbi Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity
    Wasana K Sumanasekera
    Center for Molecular Toxicology and Carcinogenesis and Department of Veterinary Science, The Pennsylvania State University, University Park, Pennsylvania 16802, USA
    Biochemistry 42:10726-35. 2003
    ..Thus, we describe the chaperone complex as being a regulator of PPARalpha and PPARbeta activity and have identified a novel, subtype-specific, inhibitory role for Hsp90...
  23. ncbi Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans
    Cynthia L David
    Steele Memorial Children's Research Center, University of Arizona, Tucson, AZ 85724, USA
    Cell Stress Chaperones 8:93-104. 2003
    ..These findings provide new insights into the nature of unusual N-terminal nucleotide-binding fold of Hsp90 and suggest that target-related drug resistance is unlikely to emerge in patients receiving GA-like chemotherapeutic agents...
  24. ncbi Antimyeloma activity of heat shock protein-90 inhibition
    Constantine S Mitsiades
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston MA 02115, USA
    Blood 107:1092-100. 2006
    ....
  25. ncbi Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models
    Jefferson Terry
    Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 11:5631-8. 2005
    ....
  26. ncbi Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
    Ramesh K Ramanathan
    Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
    Clin Cancer Res 11:3385-91. 2005
    ..We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics...
  27. ncbi Geldanamycin treatment reduces delayed CA1 damage in mouse hippocampal organotypic cultures subjected to oxygen glucose deprivation
    Yi-Bing Ouyang
    Department of Anesthesia, Grant Building S272, Stanford University School of Medicine, Stanford, CA 94305 5117, USA
    Neurosci Lett 380:229-33. 2005
    ..Staining with ubiquitin to identify protein aggregates revealed reduced redistribution of ubiquitin, consistent with reduced protein aggregation likely due at least in part to induction of Hsp70 by GA...
  28. ncbi Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation
    Bo-Geon Yun
    Department of Biochemistry and Molecular Biology, 246 NRC, Oklahoma State University, Stillwater, OK 74078-3035, USA
    Exp Cell Res 307:212-23. 2005
    ....
  29. ncbi The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line
    John T Price
    Tumour Cell Migration and Metastasis Laboratory, St Vincent s Institute, Melbourne, Vistoria, Australia
    Cancer Res 65:4929-38. 2005
    ..These data suggest an important contraindication to the Hsp90 targeted cancer therapy currently undergoing clinical trial...
  30. ncbi Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors
    Jean L Grem
    Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 23:1885-93. 2005
    ..To determine the clinical toxicities of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) given as a 1-hour infusion daily for 5 days every 3 weeks...
  31. ncbi Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone
    Rongmin Zhao
    Department of Biochemistry, Medical Sciences Building, 1 King's College Circle, University of Toronto, Toronto, ON, M5S 1A8, Canada
    Cell 120:715-27. 2005
    ..These cofactors interact physically and functionally with the conserved AAA(+)-type DNA helicases Rvb1/Rvb2, which are key components of several chromatin remodeling factors, thereby linking Hsp90 to epigenetic gene regulation...
  32. ncbi Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
    Udai Banerji
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey SM2 5NG, UK
    J Clin Oncol 23:4152-61. 2005
    ..We recommend this dose for phase II clinical trials...
  33. ncbi Toxoplasma gondii Hsp90 is a potential drug target whose expression and subcellular localization are developmentally regulated
    Pablo C Echeverria
    , UB2, IIB-INTECH, CONICET-UNSAM, , C.C 164, , Prov. Buenos Aires, Argentina
    J Mol Biol 350:723-34. 2005
    ..These results thus suggest Hsp90 may play a role in stage switch...
  34. ncbi Hsp90: an emerging target for breast cancer therapy
    Jason Beliakoff
    Department of Urology, Stanford University School of Medicine, CA, USA
    Anticancer Drugs 15:651-62. 2004
    ..Given the redundancy and complexity of the molecular abnormalities present in most breast cancers, the ability of Hsp90 inhibitors to alter the activity of multiple oncogenic targets may prove of unique therapeutic benefit...
  35. ncbi Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach
    David G Hay
    Medical and Molecular Genetics, GKT School of Medicine, King's College, London, UK
    Hum Mol Genet 13:1389-405. 2004
    ..Radicicol and geldanamycin could both maintain chaperone induction for at least 3 weeks and alter the detergent soluble properties of polyQ aggregates over this time course...
  36. ncbi Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation
    Meike Broemer
    , , 13092 Berlin, Germany
    Oncogene 23:5378-86. 2004
    ..Together, these results define a dual requirement for Hsp90 as a regulator of NF-kappaB signaling by its general involvement in IKK activation and by its role in IKK homeostasis...
  37. ncbi 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models
    Angelika M Burger
    Tumor Biology Center, Albert Ludwigs University of Freiburg, Freiburg, Germany
    Anticancer Drugs 15:377-87. 2004
    ..g. with tumor regressions) to 17-AAG may be associated with modulation of Hsp90 expression. The expression of this target should be followed in clinical studies with 17-AAG...
  38. ncbi Hsp90 regulates the Fanconi anemia DNA damage response pathway
    Tsukasa Oda
    Laboratory of Molecular Genetics, Department of Molecular and Cellular Biology, Institute of Molecular and Cellular Regulation, Gunma University, 3 39 15 Showa Machi, Maebashi, Gunma 371 8512, Japan
    Blood 109:5016-26. 2007
    ....
  39. ncbi The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent
    L Whitesell
    Department of Pediatrics and Steele Memorial Children s Research Center, University of Arizona, Tucson 85724, USA
    Mol Cell Biol 18:1517-24. 1998
    ..GA did not, however, appear to restore wild-type transcriptional activating activity to mutant p53 proteins in either A1-5 cells or human breast cancer cell lines...
  40. ncbi Tyrosine phosphorylation of HSP90 within the P2X7 receptor complex negatively regulates P2X7 receptors
    Elena Adinolfi
    Institute of Molecular Physiology, Department of Biomedical Science, University of Sheffield, Sheffield S10 2TN, United Kingdom
    J Biol Chem 278:37344-51. 2003
    ..We conclude that selective tyrosine phosphorylation of P2X7 receptor-associated HSP90 may act as a negative regulator of P2X7 receptor complex formation and function...
  41. ncbi Heat shock protein 90 homeostasis controls stage differentiation in Leishmania donovani
    M Wiesgigl
    Bernhard Nocht Institute for Tropical Medicine, D-20359 Hamburg, Germany
    Mol Biol Cell 12:3307-16. 2001
    ..Our results are consistent with Hsp90 homeostasis serving as cellular thermometer for these primitive eukaryotes, controlling both the heat shock response and morphological differentiation...
  42. ncbi Targeting Hsp90: small-molecule inhibitors and their clinical development
    Tony Taldone
    Department of Medicine and Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Pharmacol 8:370-4. 2008
    ....
  43. ncbi Geldanamycin restores a defective heat shock response in vivo
    K F Winklhofer
    Department of Cellular Biochemistry, , D-82152 Martinsried, Germany
    J Biol Chem 276:45160-7. 2001
    ..Thus, our studies show that a defective stress response can be pharmacologically restored and suggest that the HSF1 deactivation pathway may play an important role in the regulation of Hsp expression...
  44. ncbi Hsp90-mediated assembly of the 26 S proteasome is involved in major histocompatibility complex class I antigen processing
    Taketoshi Yamano
    Laboratory for Immunochaperones, Research Center for Allergy and Immunology RCAI, RIKEN Yokohama Inst, Yokohama 230 0045, Japan
    J Biol Chem 283:28060-5. 2008
    ..Our results indicate that hsp90 facilitates MHC class I antigen processing through epitope production in a complex of the 26 S proteasome...
  45. ncbi The anti-proliferative effect of inhibitor of telomerase on cultured retinal pigment epithelial cells
    Y Xiang
    Department of Ophthalmology, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022
    J Tongji Med Univ 21:174-6. 2001
    ..It was concluded that telomerase and Hsp90 can promote the proliferation of the cultured RPE cells, while the inhibitor of them can induce apoptosis and inhibit the growth of the RPE cells...
  46. ncbi A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors
    Archie N Tse
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:6704-11. 2008
    ..We conducted a phase I study of irinotecan and the Hsp90 inhibitor 17AAG, which can also down-regulate Chk1, in patients with solid tumors...
  47. ncbi Geldanamycin-induced destabilization of Raf-1 involves the proteasome
    T W Schulte
    Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Biochem Biophys Res Commun 239:655-9. 1997
    ..Signaling through this pathway was inhibited by GA, concomitant with loss of Raf-1 protein, but was restored if Raf-1 was protected from GA-induced degradation by proteasome inhibitors...
  48. ncbi 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis
    Markus David Siegelin
    Department of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 220, 69120 Heidelberg, Germany
    Neurobiol Dis 33:243-9. 2009
    ..In addition, over-expression of survivin attenuated cytotoxicity induced by the combination of 17-AAG and TRAIL. In summary, survivin is a key regulator of TRAIL-17-AAG mediated cell death in malignant glioma...
  49. ncbi Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1
    M J Egorin
    Division of Developmental Therapeutics, University of Maryland Cancer Center, Baltimore, MD 21201, USA
    Cancer Chemother Pharmacol 47:291-302. 2001
    ..v., i.p., or orally. 17AAG is widely distributed to tissues. These pharmacokinetic data generated have proven relevant to the design of recently initiated clinical trials of 17AAG and could be useful in their interpretation...
  50. ncbi Heat shock protein 90 is important for Sp1 stability during mitosis
    Shao An Wang
    Institute of Biosignal Transduction, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan 701, Taiwan
    J Mol Biol 387:1106-19. 2009
    ..Taken together, Hsp90 is important for maintaining Sp1 stability during mitosis by the JNK-1-mediated phosphorylation of Sp1 to enable division into daughter cells and to regulate the expression of related genes in the interphase...
  51. ncbi Hsp-90 and the biology of nematodes
    Nik A I I N Him
    Parasitology Group, Institute of Comparative Medicine, School of Veterinary Medicine, University of Glasgow, Bearsden Road, Glasgow G61 1QH, UK
    BMC Evol Biol 9:254. 2009
    ..We combined these data with codon evolution models in an attempt to identify whether hsp-90 from GA-binding and non-binding species has evolved under different evolutionary constraints...
  52. ncbi Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90
    W Xu
    Department of Cell and Cancer Biology, Medicine Branch, NCI, National Institutes of Health, Rockville, Maryland 20850, USA
    J Biol Chem 276:3702-8. 2001
    ..These data suggest that Hsp90 uniquely stabilizes ErbB2 via interaction with its kinase domain and that GA stimulates ErbB2 degradation secondary to disruption of ErbB2/Hsp90 association...
  53. ncbi In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis
    W M Obermann
    Department of Cellular Biochemistry, Max Planck Institut fur Biochemie, D 82152 Martinsried, Germany
    J Cell Biol 143:901-10. 1998
    ..Our results establish Hsp90 as an ATP-dependent chaperone...
  54. ncbi Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2
    Andrea D Basso
    Program in Pharmacology, Weill Graduate School of Medical Sciences, Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Oncogene 21:1159-66. 2002
    ..Thus, pharmacological inhibition of Akt activation is achievable with ansamycins and may be useful for the treatment of HER2 driven tumors...
  55. ncbi Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells
    Jonathan A Schumacher
    Associated and Regional University Pathologists ARUP, Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
    Proteomics 7:2603-16. 2007
    ..Our studies reveal some of the molecular and proteomic consequences of Hsp90 inhibition in ALK-positive ALCL cells and provide novel insights into the mechanisms of its diverse cellular effects...
  56. ncbi Involvement of human heat shock protein 90 alpha in nicotine-induced apoptosis
    Yu-Ping Wu
    Department of Biochemistry, School of Medicine, Chiba University, Chiba City, Chiba, Japan
    Int J Cancer 100:37-42. 2002
    ..Thus, it was suggested that nicotine induces apoptosis, possibly via Hsp90 alpha expression, in human cells tested...
  57. ncbi Synthesis of a red-shifted fluorescence polarization probe for Hsp90
    Kamalika Moulick
    Program in Molecular Pharmacology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Bioorg Med Chem Lett 16:4515-8. 2006
    ..The synthesis of a red-shifted cy3B-GM ligand and its evaluation as a fluorescence polarization probe for Hsp90 is presented...
  58. ncbi A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
    G Chiosis
    Program in Cell Biology and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Chem Biol 8:289-99. 2001
    ..e. steroid receptors, Her2, Raf). We have used the structural features of this pocket to design a small molecule inhibitor of Hsp90...
  59. ncbi Inhibitors of the HSP90 molecular chaperone: current status
    Swee Sharp
    Signal Transduction and Molecular Pharmacology Team, Cancer Research UK, Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, SM2 5NG, United Kingdom
    Adv Cancer Res 95:323-48. 2006
    ..Thus, it is not surprising that new HSP90 agents are under development against this novel target for cancer therapy and several show promise...
  60. ncbi Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein
    Masahiro Waza
    Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, 466-8550 Nagoya, Japan
    J Mol Med 84:635-46. 2006
    ..This review will consider our research findings and discuss the possibility of a clinical application of 17-AAG to SBMA and other neurodegenerative diseases...
  61. ncbi Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1
    Barbara Zsebik
    Department of Biophysics and Cell Biology, Faculty of Medicine, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
    Immunol Lett 104:146-55. 2006
    ....
  62. ncbi Hsp90 inhibitors as novel cancer chemotherapeutic agents
    Len Neckers
    Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, 9610 Medical Center Drive, Suite 300, Rockville, MD 20850, USA
    Trends Mol Med 8:S55-61. 2002
    ..Because of the chemoprotective activity of several proteins that are Hsp90 clients, the combination of an Hsp90 inhibitor with a standard chemotherapeutic agent could dramatically increase the in vivo efficacy of the therapeutic agent...
  63. ncbi Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
    Ami Citri
    Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
    EMBO J 21:2407-17. 2002
    ..Based upon a model for drug-induced degradation of ErbB-2, we propose a general strategy for selective destruction of oncoproteins by targeting their interaction with molecular chaperones...
  64. ncbi Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage
    Catherine R Barker
    The Henry Wellcome Laboratory of Molecular and Cellular Gastroenterology, Division of Gastroenterology, School of Clinical Sciences, University of Liverpool, Crown Street, Liverpool L69 3BX, UK
    Nucleic Acids Res 34:1148-57. 2006
    ....
  65. ncbi Identification of AHBA biosynthetic genes related to geldanamycin biosynthesis in Streptomyces hygroscopicus 17997
    Weiqing He
    Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Tiantan Xili No 1, Beijing, 100050, China
    Curr Microbiol 52:197-203. 2006
    ..This is the first report on the AHBA biosynthetic gene cluster in a geldanamycin-producing strain...
  66. ncbi Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate
    Tri K Nguyen
    Department of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
    Clin Cancer Res 12:2239-47. 2006
    ..This strategy warrants further attention in Bcr/abl(+) hematopoietic malignancies, particularly those resistant to Bcr/abl kinase inhibitors...
  67. ncbi Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis
    Sharon Sanderson
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Surrey, United Kingdom
    Mol Cancer Ther 5:522-32. 2006
    ....
  68. ncbi The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?
    Catherine R Barker
    The Henry Wellcome Laboratory of Molecular and Cellular Gastroenterology, Division of Gastroenterology, School of Clinical Sciences, The University of Liverpool, Liverpool, United Kingdom
    Int J Cancer 118:2685-93. 2006
    ....
  69. ncbi AEG3482 is an antiapoptotic compound that inhibits Jun kinase activity and cell death through induced expression of heat shock protein 70
    Amir H Salehi
    Centre for Neuronal Survival, Montreal Neurological Institute, McGill University, Quebec, Canada
    Chem Biol 13:213-23. 2006
    ..These studies establish that AEG3482 inhibits JNK activation and apoptosis by a mechanism involving induced expression of HSP proteins...
  70. ncbi ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia
    Januario E Castro
    Moores University of California San Diego UCSD Cancer Center, University of California, CA 92093 0960, USA
    Blood 106:2506-12. 2005
    ..Additionally, ZAP-70 expression in CLL cells confers markedly heightened sensitivity to 17-AAG or 17-DMAG, suggesting that these or other Hsp90 inhibitors could be valuable therapeutically in patients with aggressive CLL...
  71. ncbi Involvement of calcium in the differential induction of heat shock protein 70 by heat shock protein 90 inhibitors, geldanamycin and radicicol, in human non-small cell lung cancer H460 cells
    Yuo-Sheng Chang
    Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan 30013, Republic of China
    J Cell Biochem 97:156-65. 2006
    ..Taken together, our findings suggest that differential calcium signaling may account for the differential induction of HSP and the action of GA and RA...
  72. ncbi In vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin in rats
    H P Behrsing
    SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025, USA
    Toxicol In Vitro 19:1079-88. 2005
    ..Hepatocellular injury was evident only at high dose exposures. This is believed to be the first use of an in vitro liver tissue model to accurately predict the differential and concentration-dependent toxicities of these compounds...
  73. ncbi Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors
    Nadia O Ibrahim
    Cell Physiology Group, Medical Faculty, Martin Luther University Halle, Halle, Germany
    Cancer Res 65:11094-100. 2005
    ..In summary, these results suggest that dosage will be a critical factor in the treatment of tumor patients with HSP90 inhibitors...
  74. ncbi Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins
    Takeshi Shimamura
    Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 65:6401-8. 2005
    ..These data suggest mutational activation of EGFR is associated with dependence on Hsp90 for stability and that Hsp90 inhibition may represent a novel strategy for the treatment of EGFR-mutant NSCLC...
  75. ncbi Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin
    Rochelle Bagatell
    Steele Memorial Children s Research Center and The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Int J Cancer 113:179-88. 2005
    ..Our findings suggest that Hsp90 inhibitors may prove useful either alone or as a component of multi-drug regimens in the treatment of neuroblastoma and osteosarcoma...
  76. ncbi In vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin using dog liver slices
    Khalid Amin
    SRI International, Menlo Park, California 94025, USA
    Toxicol Sci 87:442-50. 2005
    ..Dog liver slices can thus be used to evaluate species-, compound-, and concentration-dependent differences in toxicity...
  77. ncbi Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives
    Anna C Maroney
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Spring House, Pennsylvania 19477, USA
    Biochemistry 45:5678-85. 2006
    ....
  78. ncbi Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism
    Fei Dou
    Department of Genetics and Development Biology, Southeast University Medical School, Nanjing 210009, China
    Acta Biochim Biophys Sin (Shanghai) 37:501-5. 2005
    ..Treating cells with Hsp90 inhibitors facilitates Raf degradation, thereby down-regulating the activity of ERK...
  79. ncbi Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation
    Yuehai Shen
    Department of Physiology, Michigan State University, East Lansing, MI 48864, USA
    Bioorg Med Chem 13:4960-71. 2005
    ..Assessment is made of structural requirements for such an activity and evidence is given that distinguishes the target of such an activity from that of heat shock protein 90...
  80. ncbi Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90
    Anthea Hardcastle
    Haddow Laboratories, Cancer Research UK Centre for Cancer Therapeutics at Institute of Cancer Research, Sutton, Surrey, UK
    Assay Drug Dev Technol 3:273-85. 2005
    ..Finally, comparison is made between the use and applicability of this type of immunoassay and other techniques such as western blotting, immunohistochemistry, and flow cytometry analysis...
  81. ncbi Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography
    E B Agnew
    Developmental Therapeutics Department, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD 20889, USA
    J Chromatogr B Biomed Sci Appl 755:237-43. 2001
    ..This assay was able to measure plasma concentrations of AAG, the lower limit of quantitation being 12.5 nM, at a starting dose of 10 mg/m2 infused intravenously over 1 h in a Phase I clinical trial in adult patients with solid tumors...
  82. ncbi Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells
    Hsiu-Chin Huang
    Director Office, Animal Technology Institute Taiwan, Chunan, Miaoli
    Life Sci 70:1763-75. 2002
    ..Conversely, HSP90 did not markedly increase in all treatments. Based on the results in this study, we suggest that apoptosis induced by TSA can be prevented by GA-induced increment of heat shock proteins, particularly HSP70...
  83. ncbi ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin
    Vicki Smith
    CRC Center for Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
    Anticancer Res 22:1993-9. 2002
    ..These data suggest that erbB2 status in ovarian cancr may contribute to chemosensitivity, in some cases leading to increased sensitivity (as with geldanamycin) but in other cases leading to resistance (as with cisplatin)...
  84. ncbi Activation of mitogen-activated protein kinases during granulocyte apoptosis in patients with severe sepsis
    Luc Härter
    Division of Trauma Surgery, University Hospital Zurich, Switzerland
    Shock 18:401-6. 2002
    ..Although the ERK kinase regulates LPS-induced reduction of apoptosis, the p38 MAP kinase might be involved in IFN-gamma signaling and the feedback regulation of neutrophil apoptosis...
  85. ncbi Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha
    Monica G Marcu
    Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, USA
    Mol Cell Biol 22:8506-13. 2002
    ..These data establish a role for HSP90 in the cellular transcriptional response to ER stress and demonstrate that chaperone systems on both sides of the ER membrane serve to integrate this signal transduction cascade...
  86. ncbi Heat shock protein and proteasome targeting agents
    Chris H Takimoto
    Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Hematol Oncol Clin North Am 16:1269-85. 2002
    ..Although more research is needed to clarify the precise spectrum of antitumor activity of proteasome inhibitors, this novel approach to targeting human malignancies is highly promising...
  87. ncbi ErbB2 degradation mediated by the co-chaperone protein CHIP
    Pengcheng Zhou
    Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 278:13829-37. 2003
    ....
  88. ncbi 17AAG: low target binding affinity and potent cell activity--finding an explanation
    Gabriela Chiosis
    Program in Cell Biology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cancer Ther 2:123-9. 2003
    ..We suggest that in the clinic, micromolar concentrations of 17AAG must accumulate in the tumor cells to achieve antitumor effects in patients comparable with ones achieved in tissue culture settings...
  89. ncbi [Molecular chaperone HSP90 as a novel target for cancer chemotherapy]
    Yoshihiko Miyata
    Department of Cell and Developmental Biology, Graduate School of Biostudies, Kyoto University, Kitashirakawa, Oiwake cho, Sakyo ku, Kyoto 606 8502, Japan
    Nihon Yakurigaku Zasshi 121:33-42. 2003
    ..In fact, a modified geldanamycin with lower toxicity, 17-allylaminogeldanamycin (17-AAG), has been examined in phase I clinic trials with encouraging results...
  90. ncbi Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts
    R Nimmanapalli
    Interdisciplinary Oncology Program, Moffitt Cancer Center, University of South Florida, Tampa 33612, USA
    Cancer Res 61:1799-804. 2001
    ..These data establish the in vitro activity of GA and 17-AAG against Bcr-Abl-positive leukemic cells and support the in vivo investigation of 17-AAG against Bcr-Abl-positive leukemias...
  91. ncbi Soluble fibrinogen modulates neutrophil functionality through the activation of an extracellular signal-regulated kinase-dependent pathway
    Carolina Rubel
    Division Inmunologia, Instituto de Investigaciones Hematologicas, Academia Nacional de Medicina, Buenos Aires, Argentina
    J Immunol 168:3527-35. 2002
    ..In the context of an inflammatory process, the intracellular signal pathway activated by sFbg may be an early event influencing the functionality of PMN...
  92. ncbi Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein
    M Ergin
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Exp Hematol 29:1082-90. 2001
    ..These findings further suggest that therapies targeting tyrosine kinases, including p80, may have clinical utility...
  93. ncbi Phosphorylation-induced activation of tilapia nonspecific cytotoxic cells by serum cytokines
    J Ruiz
    Department of Medical Microbiology and Parasitology, College of Veterinary Medicine, University of Georgia, Athens 30602-7386, USA
    Dis Aquat Organ 46:129-37. 2001
    ..Activation was associated with increased phosphorylation and higher cytotoxic effector functions...
  94. ncbi Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin
    J Yang
    University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Departments of Medicine and Pharmacology, The Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA
    Cancer Res 61:4010-6. 2001
    ..These studies demonstrate for the first time the activity of GAs against human gliomas in vitro and in vivo and suggest that destruction of EF-2 kinase may be an important cytotoxic mechanism of this unique class of drug...
  95. ncbi Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
    P N Munster
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:2945-52. 2001
    ..G1 arrest is sufficient for some but not all aspects of the phenotype. Induction of differentiation may be responsible for some of the antitumor effects of this drug...
  96. ncbi Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis
    Patricia Murphy
    Department of Anesthesiology, University of Illinois, 1819 West Polk Street, Chicago, IL 60612, USA
    J Neurosci Res 67:461-70. 2002
    ..These results indicate that ansamycins can exert potent anti-inflammatory effects on brain glial cells which may provide therapeutic benefit in neuroinflammatory diseases...
  97. ncbi Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1
    F S Goes
    Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, Rhode Island 02912, USA
    Eur J Biochem 268:2281-9. 2001
    ....
  98. ncbi Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2
    V Boudny
    Department of Medicine and Biosystemic Science, Graduate School of Medicine, Kyushu University, 3 1 1 Maidashi, Higashi ku, Fukuoka, Fukuoka 812 8582, Japan
    Br J Cancer 86:463-9. 2002
    ....
  99. ncbi CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins
    Howard Doong
    Molecular Signaling Section, Laboratory of Pathology and Regulation of Protein Function Laboratory, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 278:28490-500. 2003
    ..Furthermore, poly-ubiquitination is not sufficient for efficient proteasomal targeting of Hsp client proteins...
  100. ncbi Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells
    Raffaella Villa
    Department of Experimental Oncology, Unit 10, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Carcinogenesis 24:851-9. 2003
    ....
  101. ncbi Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction
    Irina A Vasilevskaya
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 63:3241-6. 2003
    ..2 but not in HCT116 cells, which we postulate to be the basis for higher survival of p53-deficient cells when treated with combinations of the two drugs...

Research Grants119 found, 100 shown here

  1. ORGANOMETALLIC SYNTHESES OF BIOACTIVE COMPOUND
    LOUIS HEGEDUS; Fiscal Year: 1993
    ..This ability is simply unavailable using conventional methodology...
  2. Assays for rapid identification of Hsp70 modulators
    Gabriela Chiosis; Fiscal Year: 2007
    ....
  3. Hsp90 inhibitors as suppressors of protein misfolding toxicity
    Gabriela Chiosis; Fiscal Year: 2007
    ..In conclusion, Hsp90- interfering drugs represent a potential novel class of drugs to promote the survival of neurons and open up a promising approach to the treatment of neurodegenerative diseases. ..
  4. Development of HTS assays probing Hsp90 inhibition (RMI)
    Gabriela Chiosis; Fiscal Year: 2004
    ..Hits resulted from the FP assay will be tested for Her2 degradation potency in the breast cancer cell line SKBr3. Highest ranking compounds in both screens will be taken for further testing in follow-up research programs. ..
  5. FP Assay for Isolation of Hsp90 Inhibitors (RMI)
    Gabriela Chiosis; Fiscal Year: 2005
    ....
  6. Isolation of Inhibitors of Her-Kinase Expression (RMI)
    Gabriela Chiosis; Fiscal Year: 2005
    ..To our knowledge, this has not been accomplished, and we believe that we are uniquely positioned to initiate this goal. ..
  7. CONTROL OF FIBRINOLYTIC PATHWAYS IN LUNG DISEASE
    Sreerama Shetty; Fiscal Year: 2002
    ..This work may suggest new therapeutic approaches to a variety of inflammatory or neoplastic lung diseases for which current therapy is often unsatisfactory. ..
  8. Regulation of Lung Epithelial Fibrinolysis by Urokinase
    Sreerama Shetty; Fiscal Year: 2005
    ..This information could hasten the development of new, mechanism-based interventions for lung disorders, including acute lung injury or lung neoplasia. ..
  9. Hsp90 as a Target for the Treatment of Childhood Cancer
    Rochelle Bagatell; Fiscal Year: 2007
    ..Upon completion of the award period, Dr. Bagatell will be well prepared to move forward as an independent investigator. ..
  10. CONTROL OF FIBRINOLYTIC PATHWAYS IN LUNG DISEASE
    Sreerama Shetty; Fiscal Year: 2004
    ..abstract_text> ..
  11. MODULATION OF K+ CHANNELS IN RENAL COLLECTING DUCT
    Wen Hui Wang; Fiscal Year: 2003
    ..Since the studies are conducted on freshly isolated CCD, the results will provide information essential for understanding the role of NO in the regulation of Na+ and K+ transport in the CCD. ..
  12. Targeting Cell Cycle Checkpoints in Cancer Therapeutics
    Archie Tse; Fiscal Year: 2007
    ..The proposed studies are expected to provide insights of how checkpoint defects in tumors can be exploited to render them more susceptible to combined treatment with chemotherapy and checkpoint inhibitors such as 17AAG. ..
  13. Potentiation of Topo Inhibitors by the HDACi, SAHA
    Pamela Munster; Fiscal Year: 2007
    ..These findings may be useful in the rational design of future clinical trials involving HDACi. ..
  14. MODULATION AND REGULATION OF ROMK CHANNELS IN KIDNEY
    WenHui Wang; Fiscal Year: 2004
    ..The effect of PGE2 has relevance to Bartter's Syndrome where hyperprostaglandinemia is prominent and inhibition of prostaglandin production reverses partially the physiological consequences of impaired TAL function. ..
  15. The Role of Selective HDAC Enzymes in Drug Sensitivity
    Pamela Munster; Fiscal Year: 2007
    ..In pre- and post-treatment tumor samples, we will determine which HDACs are involved in the cellular effects induced by the HDACi and which HDACs may predict response. ..
  16. SYNTHESIS OF MDR REVERSING POLYENES
    MERRITT ANDRUS; Fiscal Year: 2003
    ..This is an important first step toward a molecular understanding of the unique recognition properties, transport mechanism of Pgp, and will further facilitate the design of new, more potent reversal agents. ..
  17. MODULATION AND REGULATION OF ROMK CHANNELS IN KIDNEY
    WenHui Wang; Fiscal Year: 2009
    ..Specific Aim 2 To examine whether mono-ubiquitination of ROMK channels is regulated by PKA and PTK. Specific aim 3 To explore the role of CD63 in mediating ROMK1 tyrosine phosphorylation and mono-ubiquitination. ..
  18. Potentiation of Topo Inhibitors by HDAC Inhibitors
    Pamela Munster; Fiscal Year: 2005
    ..Finally, the utility of the topo II inhibitors could be enhanced if their efficacy could be increased without worsening toxicity, as our preclinical data appears to indicate. ..
  19. Modulation of K channels in renal collecting duct
    Wen Hui Wang; Fiscal Year: 2007
    ....
  20. Arsenic Trioxide Down-Regulates STAT3 Activity in AML
    Meir Wetzler; Fiscal Year: 2004
    ..In addition, we will attempt to identify the mode by which ATO controls the activity of STAT3 and how this effect alters the gene profile patterns and induces apoptosis. ..
  21. Hsp90 Chaperone Machine Structure and Function
    Avrom Caplan; Fiscal Year: 2009
    ..In the second sub-aim we will assay for chaperone activity of novel co-chaperones that are important for protein kinase folding. Finally, we will distinguish between the role of Cdc37 in Cdk folding and cyclin binding. ..
  22. Prostanoids and hypoxic neonatal pulmonary hypertension
    CANDICE FIKE; Fiscal Year: 2009
    ..The goal of this project is to help us understand why infants develop pulmonary hypertension, determine what happens in the lung blood vessels during disease development, and develop treatments for this disease. ..
  23. Novel Eicosanoids: Synthesis and Function
    John Falck; Fiscal Year: 2009
    ..It is the long-term objective of this laboratory to identify these metabolites, develop biochemical and chemical tools to better understand their physiologic roles, and ultimately intervene pharmacologically. ..
  24. Signal Transduction in the Heart after Cancer Therapy
    Kathleen Gabrielson; Fiscal Year: 2009
    ..The public health significance of this project is that we aim to protect patients from severe cardiotoxic effects of anti-cancer drugs, which in many cases, limits the use of otherwise effective therapies. ..
  25. Signal Transduction in the Heart after Cancer Therapy
    KATHLEEN LOUISE GABRIELSON; Fiscal Year: 2010
    ..The public health significance of this project is that we aim to protect patients from severe cardiotoxic effects of anti-cancer drugs, which in many cases, limits the use of otherwise effective therapies. ..
  26. Defibrotide for the treatment of severe hepatic veno-cc*
    Paul Richardson; Fiscal Year: 2007
    ..Abstract Not Provided ..
  27. Signal Transduction in the Heart after Cancer Therapy
    Kathleen Gabrielson; Fiscal Year: 2009
    ..The public health significance of this project is that we aim to protect patients from severe cardiotoxic effects of anti-cancer drugs, which in many cases, limits the use of otherwise effective therapies. ..
  28. Brain Manganese Deposition in High Risk Neonates
    Judy Aschner; Fiscal Year: 2007
    ..The proposed clinical investigation has enormous health significance and may shed light on the development and progression of neurological dysfunction in infants and children on prolonged parenteral nutrition. ..
  29. Novel Eicosanoids: Synthesis and Function
    John Falck; Fiscal Year: 2007
    ..3) Develop isozyme-specific P450 inhibitors using (i) structure based rational design; (ii) computational/molecular modeling; and (iii) library screening. ..
  30. Novel Eicosanoids: Synthesis and Function
    John R Falck; Fiscal Year: 2010
    ..It is the long-term objective of this laboratory to identify these metabolites, develop biochemical and chemical tools to better understand their physiologic roles, and ultimately intervene pharmacologically. ..
  31. ANDROGEN RECEPTOR DEGRADATION
    Avrom Caplan; Fiscal Year: 2006
    ..abstract_text> ..
  32. NOVEL EICOSANOIDS--ANALYSIS, SYNTHESIS, AND FUNCTION
    John Falck; Fiscal Year: 1999
    ..and (e) elucidation of the P450 active site. ..
  33. EICOSANOID SYNTHESIS
    John Falck; Fiscal Year: 1991
    ..In light of the almost universal distribution of cytochrome P-450 in mammalian tissues, this work will have profound implications for our understanding of fatty acid metabolism and its relationship to homeostasis...
  34. Biochemical Effects of Disrupting HSP90
    Charles Erlichman; Fiscal Year: 2004
    ....